Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics
NewLimit Raises $435 Million Series C Ahead of First Clinical Trial for Longevity Medicine
00

NewLimit Raises $435 Million Series C Ahead of First Clinical Trial for Longevity Medicine

Jun 2, 2026

NewLimit announced a $435 million Series C funding round on June 2, 2026, led by Founders Fund with participation from Thrive Capital, Lilly Ventures, Nat Friedman, and Daniel Gross. The South San Francisco longevity biotech, valued at around $3.1 billion, plans to launch its first clinical trial of a liver medicine. Founded in 2021 by Coinbase CEO Brian Armstrong, Blake Byers, and Jacob Kimmel, NewLimit previously raised $130 million in May 2025.

Series C funding round

  • ▪NewLimit's Series C funding round included participation from Thrive Capital, Lilly Ventures, Nat Friedman, and Daniel Gross
  • ▪NewLimit raised $435 million in a Series C funding round
  • ▪NewLimit announced its Series C fundraising on June 2, 2026
  • ▪NewLimit plans to launch its first clinical trial of a liver medicine
  • ▪Founders Fund led NewLimit's Series C financing round

Company background

  • ▪NewLimit is based in South San Francisco
  • ▪Blake Byers is a former GV partner and bioengineer
  • ▪Brian Armstrong is the CEO and co-founder of Coinbase
  • ▪NewLimit was founded in 2021 by Brian Armstrong, Blake Byers, and Jacob Kimmel
  • ▪Jacob Kimmel is a stem cell biologist
  • ▪Founders Fund is a Silicon Valley venture capital firm co-founded by Peter Thiel
  • ▪NewLimit is valued at around $3.1 billion according to co-founder and CEO Jacob Kimmel

Rapid fundraising timeline

  • ▪NewLimit raised $45 million in October 2025
  • ▪NewLimit announced three fundraising rounds in the last year
  • ▪NewLimit raised a $130 million Series B round in May 2025

1 source

Statnews
Longevity startup NewLimit raises $435 million ahead of first clinical trial
View source article

Featured stories

View more in Clinical evaluation

LangChain raises $300 million at $3 billion valuation

Nov 12, 2026 · 2 sources

Q-CTRL raises $290 million Series C at over $1 billion valuation for quantum software

Nov 12, 2026 · 3 sources

Norwest raises $4 billion fund focused on AI investments

Nov 12, 2026 · 2 sources

Fractile raises $720 million Series C at $7 billion valuation for AI chips

Nov 11, 2026 · 3 sources

Story comments

Loading comments…

Related entities

Series C

Topics

Clinical evaluationDrug Approval and Clinical TrialsDrug Policy, Pricing & ApprovalLongevity & agingClinical trialsLongevity biotech foundersLifestyle, Wellness and NutritionLongevity & biohackingAI startupsPharmaClinical Trial Design & Evaluation

Featured stories

View more in Clinical evaluation

LangChain raises $300 million at $3 billion valuation

Nov 12, 2026 · 2 sources

Q-CTRL raises $290 million Series C at over $1 billion valuation for quantum software

Nov 12, 2026 · 3 sources

Norwest raises $4 billion fund focused on AI investments

Nov 12, 2026 · 2 sources

Fractile raises $720 million Series C at $7 billion valuation for AI chips

Nov 11, 2026 · 3 sources